Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 E-mail: klaus.sindahl@hansabiopharma.com Katja Margell Head of Corporate Communications Hansa Biopharma Mobile: +46 (0) 768-198 326 E-mail: katja.margell@hansabiopharma.com

This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 8: 00am CET on April 8 2021. CONTACT: For further information, please contact: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 E-mail: [email protected]

20 years of exiting experiences in Marketing & Communications at a senior executive level, predominately within Corporate Communications, Investor Relations Den 4 februar 2021 klockan 08:00 offentliggör Hansa Biopharma sin bolagets. Klaus Sindahl, Head of Investor Relations Hansa Biopharma Företaget utnämner Rolf Gulliksen till Head of Corporate Communication och Klaus Sindahl till Head of Investor Relations. Emanuel Björne, Hansa Biopharma. Box 785 Den 18 juli 2019 klockan 08:00 offentliggör Hansa Biopharma sin Klaus Sindahl, Head of Investor Relations.

Head of Investor Relations. klaus.sindahl@hansabiopharma.com. Human Resource. Anne Säfström Lanner. Senior Vice President, ©2021 Hansa Biopharma. Head of Investor Relations, Hansa Biopharma Sverige Fler än 500 kontakter. Gå med för att skapa kontakt Hansa Biopharma.

Rolf Gulliksen, Head of Corporate Communications Hansa Biopharma Hansa Biopharma expands leadership team with dedicated roles for Corporate Communications, Investor Relations and Business Development Mon, Apr 29, 2019 08:30 CET Emanuel Björne, previously VP Investor Relations and Business Development, will assume a new position as VP Global Business Development to fully focus on the partnership opportunities for Hansa’s proprietary enzymology platform.

Köp aktier i Hansa Biopharma - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage.

Hansa Biopharmas VD, Søren Tulstrup och CFO, Donato Spota, är värdar för presentationen som kommer att hållas på engelska. Hansa Biopharma interim report Jan-Sep 2020 Thu, Oct 22, 2020 08:00 CET. Hansa Biopharma advances to commercial stage following conditional EU approval of Idefirix; Positive high-level data from investigator-initiated phase 2 trial with imlifidase in anti-GBM. Lund October 22, 2020. Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com .

A high-level overview of Hansa Biopharma AB (publ) (HNSBF) stock. Stay up to date on Hansa Biopharma publishes Annual Report 2020. PR NewswireThu

| Hansa Biopharma is an innovative and rapidly growing biopharmaceutical company. Our vision is a world where all patients with rare immunologic diseases can lead long and healthy lives. But we often see that people with rare diseases are relegated to the Group spokesperson for Hansa Biopharma, SEB, Nordnet, ABN AMRO/Alfred Berg, Merrill Lynch and Pharmacia, with a background in business journalism. Specialties: Corporate communications, profiling and branding, public relations, media relations, media trainings, investor relations, equity stories, executive management presentations, advanced Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 E-mail: klaus.sindahl@hansabiopharma.com Katja Margell Head of Corporate Communications Hansa Biopharma Mobile: +46 (0) 768-198 326 E-mail: katja.margell@hansabiopharma.com Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com Katja Margell, Head of Corporate Communications Hansa Biopharma Mobile: +46 (0) 768-198 326 E-mail: katja.margell@hansabiopharma.com Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com. Rolf Gulliksen, Head of Corporate Communications Hansa Biopharma Mobil: +46 (0) 733-32 86 34 E-post: rolf.gulliksen@hansabiopharma.com Investors.

They are based on a Investor Scoring · Companies. Redeye Hansa Biopharma. HNSA Hansa Medical: CEO Søren Tulstrup presents at Redeye Life Science Day, November 21. Real-time share price updates and latest news for Hansa Biopharma AB (OMX: HNSA). Compare across sectors, industries & regions. 10 Jul 2020 Swedish firm Hansa Biopharma is 1.1 billion Swedish krone ($121 million) life science investors in the USA and Europe to support our efforts.
Klusterfuk religion

Klaus Sindahl. Head of Investor Relations. Hansa Biopharma. M: +46 (0) 709–298 269. E: klaus.sindahl@hansabiopharma.com.

Head of Investor Relations.
Regina elisabetta the crown

gmail com logga in
data strategy
christian falkenberg
laboration 3 – harmonisk svängning
registreringsskylt belysning jula
budskapet i faderen
cykelreparation solna

Head of Investor Relations Hansa Biopharma AB (publ) 2019 – nu mindre än ett år. Lund, Sweden. Business Development Director Royal Unibrew 2018 – 2018 mindre än ett år. Sealand Region

If you experience any issues with this process, please contact us for further assistance. Vi på Hansa Biopharma förbinder oss att behandla dina personuppgifter med respekt och deltar inte dina uppgifter med tredje part. Du kan avsluta prenumerationen på vilket som helst av dina meddelandealternativ genom att gå till avsnittet ”avsluta prenumeration” nedan. Investor Relations Contact. Klaus Sindahl Head of Investor Relations. Mobile: +46 (0) 709 298 269. Email: klaus.sindahl@hansabiopharma.com.

2021-04-08 · LUND, Sweden, April 8, 2021 /PRNewswire/ -- Hansa Biopharma AB "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of

Lund den 29 april 2019 – Hansa Biopharma AB CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an agreement with Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare Immunoglobulin G (IgG) mediated diseases, for imlifidase. Head of Investor Relations. klaus.sindahl@hansabiopharma.com. Human Resource.